Cargando...
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, alrea...
Guardado en:
| Publicado en: | Cardiovasc Diabetol |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6393994/ https://ncbi.nlm.nih.gov/pubmed/30819210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0828-y |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|